Waldemar Halota

14 Żurawia St
Bialystok, PD 15540, Poland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 65 publications

Prevalence and predictors of HCV infection among hospitalized psychiatric patients in Poland.

Prevalence and predictors of HCV infection among hospitalized psychiatric patients in Poland.

Journal: Frontiers in psychiatry

Published: March 20, 2026

Hepatitis C Infection as a Risk Factor for Hypertension and Cardiovascular Diseases: An EpiTer Multicenter Study.

Hepatitis C Infection as a Risk Factor for Hypertension and Cardiovascular Diseases: An EpiTer Multicenter Study.

Journal: Journal of clinical medicine

Published: July 23, 2022

HCV Genotype Has No Influence on the Incidence of Diabetes-EpiTer Multicentre Study.

HCV Genotype Has No Influence on the Incidence of Diabetes-EpiTer Multicentre Study.

Journal: Journal of clinical medicine

Published: December 09, 2021

Effectiveness and Safety of Pangenotypic Regimens in the Most Difficult to Treat Population of Genotype 3 HCV Infected Cirrhotics.

Effectiveness and Safety of Pangenotypic Regimens in the Most Difficult to Treat Population of Genotype 3 HCV Infected Cirrhotics.

Journal: Journal of clinical medicine

Published: June 13, 2021

Factors influencing the failure of interferon-free therapy for chronic hepatitis C: Data from the Polish EpiTer-2 cohort study.

Factors influencing the failure of interferon-free therapy for chronic hepatitis C: Data from the Polish EpiTer-2 cohort study.

Journal: World journal of gastroenterology

Published: January 26, 2021

Real-world direct-acting antiviral treatment in kidney transplant and hemodialysis patients: the EpiTer-2 multicenter observational study.

Real-world direct-acting antiviral treatment in kidney transplant and hemodialysis patients: the EpiTer-2 multicenter observational study.

Journal: Annals of gastroenterology

Published: September 13, 2020

Is an 8-week regimen of glecaprevir/pibrentasvir sufficient for all hepatitis C virus infected patients in the real-world experience?

Is an 8-week regimen of glecaprevir/pibrentasvir sufficient for all hepatitis C virus infected patients in the real-world experience?

Journal: Journal of gastroenterology and hepatology

Published: September 10, 2020

Real-world effectiveness and safety of direct-acting antivirals in patients with cirrhosis and history of hepatic decompensation: Epi-Ter2 Study.

Real-world effectiveness and safety of direct-acting antivirals in patients with cirrhosis and history of hepatic decompensation: Epi-Ter2 Study.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: August 30, 2020

Recommendations of the Polish Group of Experts for HCV for the treatment of hepatitis C in 2020.

Recommendations of the Polish Group of Experts for HCV for the treatment of hepatitis C in 2020.

Journal: Clinical and experimental hepatology

Published: July 14, 2020

Low risk of HBV reactivation in a large European cohort of HCV/HBV coinfected patients treated with DAA.

Low risk of HBV reactivation in a large European cohort of HCV/HBV coinfected patients treated with DAA.

Journal: Expert review of anti-infective therapy

Published: June 16, 2020

Searching for the optimal population for hepatitis C virus screening in Poland.

Searching for the optimal population for hepatitis C virus screening in Poland.

Journal: Clinical and experimental hepatology

Published: April 24, 2020

Changes in patient profile, treatment effectiveness, and safety during 4 years of access to interferon-free therapy for hepatitis C virus infection.

Changes in patient profile, treatment effectiveness, and safety during 4 years of access to interferon-free therapy for hepatitis C virus infection.

Journal: Polish archives of internal medicine

Published: February 08, 2020

Showing 1-12 of 65

Last Updated: 09/26/2026